DePARylation is critical for S phase progression and cell survival.

NAD PARG PARG inhibitor PARylation ribosylation

Journal

bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187

Informations de publication

Date de publication:
06 Oct 2023
Historique:
pubmed: 14 8 2023
medline: 14 8 2023
entrez: 14 8 2023
Statut: epublish

Résumé

Poly(ADP-ribose)ylation or PARylation by PAR polymerase 1 (PARP1) and dePARylation by poly(ADP-ribose) glycohydrolase (PARG) are equally important for the dynamic regulation of DNA damage response. PARG, the most active dePARylation enzyme, is recruited to sites of DNA damage via pADPr-dependent and PCNA-dependent mechanisms. Targeting dePARylation is considered an alternative strategy to overcome PARP inhibitor resistance. However, precisely how dePARylation functions in normal unperturbed cells remains elusive. To address this challenge, we conducted multiple CRISPR screens and revealed that dePARylation of S phase pADPr by PARG is essential for cell viability. Loss of dePARylation activity initially induced S phase-specific pADPr signaling, which resulted from unligated Okazaki fragments and eventually led to uncontrolled pADPr accumulation and PARP1/2-dependent cytotoxicity. Moreover, we demonstrated that proteins involved in Okazaki fragment ligation and/or base excision repair regulate pADPr signaling and cell death induced by PARG inhibition. In addition, we determined that PARG expression is critical for cellular sensitivity to PARG inhibition. Additionally, we revealed that PARG is essential for cell survival by suppressing pADPr. Collectively, our data not only identify an essential role for PARG in normal proliferating cells but also provide a potential biomarker for the further development of PARG inhibitors in cancer therapy. Poly(ADP-ribosyl)ation is a reversible post-translational modification. Although PARG may have a protective effect against excessive PARP1 engagement, detailed knowledge of PARG's mechanism of action remains elusive. Here, we showed that PARG participates in DNA replication, especially in Okazaki fragment maturation. Moreover, PARG level is critically important for cellular sensitivity to PARG inhibition, which is a valuable biomarker for PARGi-based therapy.

Identifiants

pubmed: 37577639
doi: 10.1101/2023.07.31.551317
pmc: PMC10418084
pii:
doi:

Types de publication

Preprint

Langues

eng

Déclaration de conflit d'intérêts

Competing interest statement The authors declare that they have no conflicts of interest with the content of this article.

Références

DNA Repair (Amst). 2014 Nov;23:4-16
pubmed: 24865146
Nat Cell Biol. 2022 Jan;24(1):62-73
pubmed: 35013556
Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):7915-22
pubmed: 8367443
Cancer Res. 2012 Nov 1;72(21):5588-99
pubmed: 23118055
Sci Adv. 2019 Apr 10;5(4):eaav4340
pubmed: 30989114
Mol Cell. 2021 Jun 17;81(12):2640-2655.e8
pubmed: 34019811
NAR Cancer. 2021 Nov 17;3(4):zcab044
pubmed: 34806016
Mol Cell. 2015 Sep 17;59(6):998-1010
pubmed: 26365379
Nucleic Acids Res. 2017 Aug 21;45(14):8129-8141
pubmed: 28854736
Front Biosci (Landmark Ed). 2009 Jan 01;14(5):1619-26
pubmed: 19273151
Nat Cell Biol. 2021 Dec;23(12):1287-1298
pubmed: 34811483
Oncogene. 2019 Mar;38(12):2177-2191
pubmed: 30459355
Cell Death Dis. 2013 Jun 06;4:e656
pubmed: 23744356
Cancer Cell. 2019 Mar 18;35(3):519-533.e8
pubmed: 30889383
Trends Genet. 2019 Jun;35(6):412-422
pubmed: 31036342
Genes (Basel). 2015 Jun 23;6(2):385-98
pubmed: 26110316
Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17699-704
pubmed: 15591342
DNA Repair (Amst). 2020 Mar;87:102803
pubmed: 31991288
Proc Natl Acad Sci U S A. 2022 Jun 21;119(25):e2121779119
pubmed: 35704761
Nucleic Acids Res. 2017 Sep 19;45(16):9741-9759
pubmed: 28934471
Prog Biophys Mol Biol. 2021 Aug;163:160-170
pubmed: 33524442
Cell Cycle. 2012 Mar 1;11(5):990-7
pubmed: 22333589
Nat Neurosci. 2009 Aug;12(8):973-80
pubmed: 19633665
Nat Commun. 2022 Jul 22;13(1):4240
pubmed: 35869071
Genes Dev. 2020 Mar 1;34(5-6):360-394
pubmed: 32029455
Nature. 2018 Jul;559(7713):285-289
pubmed: 29973717
EMBO J. 1991 Dec;10(13):4351-60
pubmed: 1721870
Mol Cell. 2021 Aug 5;81(15):3128-3144.e7
pubmed: 34216544
Nat Commun. 2019 Dec 11;10(1):5654
pubmed: 31827085
DNA Repair (Amst). 2017 Apr;52:81-91
pubmed: 28254358
Nucleic Acids Res. 2011 Jul;39(12):5045-56
pubmed: 21398629
Cell. 2018 Jan 25;172(3):439-453.e14
pubmed: 29290468
DNA Repair (Amst). 2014 Nov;23:27-32
pubmed: 25283336
Cancer Res. 2003 Nov 1;63(21):7436-42
pubmed: 14612543
Cancer Res. 2019 Sep 1;79(17):4491-4502
pubmed: 31273064
Biochem J. 2005 Jun 1;388(Pt 2):493-500
pubmed: 15658938
Genes Dev. 2020 Mar 1;34(5-6):285-301
pubmed: 32029453
Mol Cell. 2018 Jul 19;71(2):319-331.e3
pubmed: 29983321
Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):18964-9
pubmed: 24191052
Curr Cancer Drug Targets. 2009 Dec;9(8):953-62
pubmed: 20025604
Genes Dev. 2020 Mar 1;34(5-6):263-284
pubmed: 32029451
Int Rev Cell Mol Biol. 2020;353:1-29
pubmed: 32381174
Mol Cell. 2021 Jul 15;81(14):3018-3030.e5
pubmed: 34102106
J Biol Chem. 2006 Jan 13;281(2):705-13
pubmed: 16278211
J Biol Chem. 1990 Dec 15;265(35):21907-13
pubmed: 2123876
Neuromolecular Med. 2009;11(1):28-42
pubmed: 19288225
Mol Cell Biol. 2015 Mar;35(5):856-65
pubmed: 25535335
Proc Natl Acad Sci U S A. 2021 Jan 26;118(4):
pubmed: 33483422
DNA Repair (Amst). 2018 Jan;61:25-36
pubmed: 29179156
J Biol Chem. 1980 Nov 10;255(21):10493-501
pubmed: 7430132
Life Sci Alliance. 2022 Sep 09;5(12):
pubmed: 36260751
Cancer Cell. 2018 Jun 11;33(6):1078-1093.e12
pubmed: 29894693
Nat Commun. 2018 May 10;9(1):1849
pubmed: 29748565
Proc Natl Acad Sci U S A. 2019 May 14;116(20):9941-9946
pubmed: 31028139
Biochem Biophys Res Commun. 2013 May 24;435(1):100-6
pubmed: 23624507
Elife. 2017 Jun 26;6:
pubmed: 28650317
Mol Cell Biol. 1994 Jan;14(1):68-76
pubmed: 8264637
Elife. 2021 Mar 08;10:
pubmed: 33683197
PLoS One. 2013;8(3):e59505
pubmed: 23555685
Mol Cell Biol. 2004 Aug;24(16):7163-78
pubmed: 15282315
PLoS Genet. 2011 Jun;7(6):e1002080
pubmed: 21655080
Nucleic Acids Res. 2021 May 21;49(9):5003-5016
pubmed: 33872376
Nucleic Acids Res. 2021 Aug 20;49(14):8214-8231
pubmed: 34320214
J Neurosci. 2010 Feb 24;30(8):2967-78
pubmed: 20181594
Mol Cell. 2016 May 5;62(3):432-442
pubmed: 27067600
Exp Cell Res. 2001 Aug 1;268(1):7-13
pubmed: 11461113
ACS Chem Biol. 2016 Nov 18;11(11):3179-3190
pubmed: 27689388
Genes Dev. 2017 Jan 15;31(2):101-126
pubmed: 28202539
Cancer Discov. 2020 Nov;10(11):1672-1689
pubmed: 32606138
Oncogene. 2021 Apr;40(14):2496-2508
pubmed: 33674744

Auteurs

Litong Nie (L)

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Chao Wang (C)

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Min Huang (M)

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Xiaoguang Liu (X)

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Xu Feng (X)

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Mengfan Tang (M)

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Siting Li (S)

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Qinglei Hang (Q)

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Hongqi Teng (H)

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Xi Shen (X)

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Li Ma (L)

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Boyi Gan (B)

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Junjie Chen (J)

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Classifications MeSH